Research Output | Dar Al-hikmah Library | IIUM Only
Background: JAK2 V617F mutation is one of the driver mutations for myeloproliferative neoplasm (MPN) and vascular thrombosis. Its allele burden impacts on clinical phenotype of the neoplasm and contributes to higher risk of vascular thrombosis, especially venous thrombosis. However, in general population with JAK2 V617F mutation without overt MPN,